| dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
| dc.contributor.author | Horgan, Denis |
| dc.contributor.author | Tanner, Marcel |
| dc.contributor.author | AGGARWAL, CHARU |
| dc.contributor.author | Thomas, David |
| dc.contributor.author | Grover, Surbhi |
| dc.contributor.author | Basel-Salmon, Lina |
| dc.contributor.author | Dienstmann, Rodrigo |
| dc.date.accessioned | 2025-03-17T10:45:01Z |
| dc.date.available | 2025-03-17T10:45:01Z |
| dc.date.issued | 2025-01-23 |
| dc.identifier.citation | Horgan D, Tanner M, Aggarwal C, Thomas D, Grover S, Basel-Salmon L, et al. Precision Oncology: A Global Perspective on Implementation and Policy Development. JCO Glob Oncol. 2025 Jan 23;11:e2400416. |
| dc.identifier.issn | 2687-8941 |
| dc.identifier.uri | http://hdl.handle.net/11351/12770 |
| dc.description | Precision Oncology; Policy development |
| dc.description.abstract | Despite the acknowledged merits of precision oncology (PO) and its increasing global implementation, its full potential for advancing care and prevention remains unrealized. The benefits are currently accessible to only limited patient segments because of multifaceted barriers. Successful implementation hinges on various factors—scientific complexities not limited to technical, clinical, regulatory, economic, administrative, and health care policy–related challenges. From building infrastructure to the associated costs, including research and development, testing, processing, and trained personnel, a lack of alignment persists. Administrative alignment with regulatory and payor acceptance is crucial. Health care policy must adapt to the ongoing shift from a one-size-fits-all treatment to a personalized approach. Without official endorsement of long-term gains over short-term costs and the health establishment's readiness for innovation, PO prospects, even in prosperous economies, may stagnate. Lower-income countries face exacerbated challenges, intensifying barriers to adoption. Nevertheless, growing awareness and utilization, driven by recognized potential for patients and public health, along with successful examples and advocacy, are progressively influencing policy for a more inclusive and beneficial approach to PO adoption. |
| dc.language.iso | eng |
| dc.publisher | American Society of Clinical Oncology |
| dc.relation.ispartofseries | JCO Global Oncology;11 |
| dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 International |
| dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ |
| dc.source | Scientia |
| dc.subject | Medicina personalitzada |
| dc.subject | Càncer - Tractament |
| dc.subject | Salut mundial |
| dc.subject | Política sanitària |
| dc.subject.mesh | Global Health |
| dc.subject.mesh | Health Policy |
| dc.subject.mesh | Neoplasms |
| dc.subject.mesh | /therapy |
| dc.subject.mesh | Precision Medicine |
| dc.subject.mesh | Policy Making |
| dc.title | Precision Oncology: A Global Perspective on Implementation and Policy Development |
| dc.type | info:eu-repo/semantics/article |
| dc.identifier.doi | 10.1200/GO-24-00416 |
| dc.subject.decs | salud global |
| dc.subject.decs | política sanitaria |
| dc.subject.decs | neoplasias |
| dc.subject.decs | /terapia |
| dc.subject.decs | medicina de precisión |
| dc.subject.decs | formulación de políticas |
| dc.relation.publishversion | https://doi.org/10.1200/GO-24-00416 |
| dc.type.version | info:eu-repo/semantics/publishedVersion |
| dc.audience | Professionals |
| dc.contributor.organismes | Institut Català de la Salut |
| dc.contributor.authoraffiliation | [Horgan D] European Alliance for Personalised Medicine, Brussels, Belgium. International Cancer Patient Coalition, Brussels, Belgium. [Tanner M] International Cancer Patient Coalition, Brussels, Belgium. Swiss Tropical & Public Health Institute/R.Geigy Foundation, Basel, Switzerland. University of Basel, Basel Switzerland. [Aggarwal C] Division of Hematology-Oncology, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA. [Thomas D] Centre for Molecular Oncology, University of New South Wales, Sydney, Australia. [Grover S] Department of Radiation Oncology, Hospital of University of Pennsylvania, Philadelphia, PA. [Basel-Salmon L] Rapahel Recanati Genetics Institute, Beilinson Hospital, Rabin Medical Center, Petach Tikva, Israel. Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. Pediatric Genetics Unit, Schneider Children’s Medical Center of Israel, Petah Tikva, Israel. Felsenstein Medical Research Center, Rabin Medical Center, Petah Tikva, Israel. [Dienstmann R] Oncology Data Science, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Oncoclínicas Precision Medicine, São Paulo, Brazil. University of Vic—Central University of Catalonia, Vic, Spain |
| dc.identifier.pmid | 39847746 |
| dc.identifier.wos | 001407288500001 |
| dc.rights.accessrights | info:eu-repo/semantics/openAccess |